Amiselimod hydrochloride NEW
| Price | $32 | $73 | $123 |
| Package | 1mg | 5mg | 10mg |
| Min. Order: | |
| Supply Ability: | 10g |
| Update Time: | 2025-04-30 |
Product Details
| Product Name: Amiselimod hydrochloride | CAS No.: 942398-84-7 |
| Purity: 99.68% | Supply Ability: 10g |
| Release date: 2025/04/30 |
Product Introduction
Bioactivity
| Name | Amiselimod hydrochloride |
| Description | Amiselimod hydrochloride (MT-1303 hydrochloride) is a sphingosine 1-phosphate receptor-1 (S1P1) modulator. |
| In vivo | After oral administration of amiselimod or fingolimod at 1 mg/kg, the concentration of amiselimod-P in rat heart tissue was relatively lower than that of fingolimod-P, potentially contributing to the minimal cardiac effects of amiselimod. Amiselimod-P showed potent selectivity for S1P1, high selectivity for S1P5, minimal agonist activity for S1P4, no distinct agonist activity for S1P2 or S1P3, and approximately 5-fold weaker GIRK activation than fingolimod-P [1]. Amiselimod 0·2 mg and 0·4 mg significantly reduced the total number of gadolinium-enhanced T1-weighted lesions [2]. |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. |
| Solubility Information | DMSO : 27 mg/mL (65.23 mM), Sonication is recommended. |
| Keywords | S1PReceptor | S1P1 | S1P Receptor | MT-1303 Hydrochloride | MT1303 Hydrochloride | MT-1303 | MT1303 | MT 1303 Hydrochloride | MT 1303 | Lysophospholipid Receptor | LPLReceptor | LPL Receptor | LPL | Inhibitor | inhibit | Amiselimod hydrochloride | Amiselimod Hydrochloride | Amiselimod |
| Inhibitors Related | Fingolimod hydrochloride | SLP9101555 | LX-2931 | Tyloxapol | CYM50374 | ASP-4058 | Ki16198 | Siponimod | Fingolimod | MP-A08 | S1PR1 modulator 1 | Ozanimod |
| Related Compound Libraries | Bioactive Compound Library | Membrane Protein-targeted Compound Library | Anti-Cancer Clinical Compound Library | Drug Repurposing Compound Library | Lipid Metabolism Compound Library | Immunology/Inflammation Compound Library | Clinical Compound Library | Bioactive Compounds Library Max | Preclinical Compound Library | GPCR Compound Library | Anti-Cancer Compound Library | Anti-Cancer Drug Library |
Company Profile Introduction
Target Molecule Corp. (TargetMol) is a global high-tech enterprise, headquartered in Boston, MA, specializing in chemical and biological research product and service to meet the research needs of global customers.
TargetMol has evolved into one of the biggest global compound library and small molecule suppliers and a customer based on 40+ countries. TargetMol offers over 80 types of compound libraries and a wide range of high-quality research chemicals including inhibitors, activator, natural compounds, peptides, inhibitory antibodies, and novel life-science kits, for laboratory and scientific use. Besides, virtual screening service is also available for customers who would like to conduct the computer-aided drug discovery.
You may like
Recommended supplier
| Product name | Price | Suppliers | Update time | |
|---|---|---|---|---|
| $32.00/1mg |
VIP5Y
|
TargetMol Chemicals Inc.
|
2025-05-16 | |
| $32.00/1mg |
VIP1Y
|
TargetMol Chemicals Inc.
|
2025-05-16 | |
| $4.90/1KG |
Hong Kong Tiansheng New Material Trading Co., Ltd
|
2021-09-24 | ||
| $4.90/1KG |
Hong Kong Tiansheng New Material Trading Co., Ltd
|
2021-09-24 |
United States- Since: 2011-01-07
- Address: 36 Washington Street, Wellesley Hill, USA
INQUIRY